Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/105974
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors |
Author: | Xiao, T. Liu, R. Proud, C. Wang, M. |
Citation: | Acta Pharmaceutica Sinica B, 2016; 6(6):557-563 |
Publisher: | Elsevier |
Issue Date: | 2016 |
ISSN: | 2211-3835 2211-3843 |
Statement of Responsibility: | Ting Xiao, Rui Liu, Christopher G.Proud, Ming-Wei Wang |
Abstract: | Eukaryotic elongation factor 2 kinase (eEF2K) inhibitors may aid in the development of new therapeutic agents to combat cancer. Purified human eEF2K was obtained from an Escherichia coli expression system and a luminescence-based high-throughput screening (HTS) assay was developed using MH-1 peptide as the substrate. The luminescent readouts correlated with the amount of adenosine triphosphate remaining in the kinase reaction. This method was applied to a large-scale screening campaign against a diverse compound library and subsequent confirmation studies. Nine initial hits showing inhibitory activities on eEF2K were identified from 56,000 synthetic compounds during the HTS campaign, of which, five were chosen to test their effects in cancer cell lines. |
Keywords: | High-throughput screening Inhibitors Luminescence MH-1 peptide eEF2K |
Rights: | © 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
DOI: | 10.1016/j.apsb.2016.04.002 |
Published version: | http://dx.doi.org/10.1016/j.apsb.2016.04.002 |
Appears in Collections: | Aurora harvest 3 Pharmacology publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_105974.pdf | Published version | 1.18 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.